News

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
LUND, SE / ACCESS Newswire / April 29, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
Morningstar7d
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
subtypes of cutaneous T-cell lymphoma (CTCL). Fast Track Designation (FTD) is intended to facilitate the development and review of drugs that treat serious conditions. "Receiving FDA's Fast Track ...
BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...
Benzinga on MSN5d
Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Soligenix recently announced an exciting update for its novel skin cancer treatment. The company reports that its flagship ...
Medscape4d
Expanded Indications for Hodgkin and CLL Drugs in Europe
The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...
Gulf Times15h
HMC highlights world-class dermatology services
As part of its ongoing 'Your Health, Our Priority' campaign, Hamad Medical Corporation (HMC) highlighted the exceptional ...
Citius Pharmaceuticals To Present At The Jefferies Global Healthcare Conference
CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, I ...